In 2014 and 2015, synthetic cannabinoid receptor agonists NNEI (N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide) and MN-18 (N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide) were detected in recreationally used and abused products in multiple countries, and were implicated in episodes of poisoning and toxicity. Despite this, the pharmacokinetic profiles of NNEI and MN-18 have not been characterized. In the present study NNEI and MN-18 were incubated in rat and human liver microsomes and hepatocytes, to estimate kinetic parameters and to identify potential metabolic pathways, respectively. These parameters and pathways were then examined in vivo, via analysis of blood and urine samples from catheterized male rats following intraperitoneal (3 mg/kg) administration of NNEI and MN-18. Both NNEI and MN-18 were rapidly cleared by rat and human liver microsomes, and underwent a range of oxidative transformations during incubation with rat and human hepatocytes. Several unique metabolites were identified for the forensic identification of NNEI and MN-18 intake. Interestingly, NNEI underwent a greater number of biotransformations (20 NNEI metabolites versus 10 MN-18 metabolites), yet parent MN-18 was eliminated at a faster rate than NNEI in vivo. Additionally, in vivo elimination was more rapid than in vitro estimates. These data highlight that even closely related synthetic cannabinoids can possess markedly distinct pharmacokinetic profiles, which can vary substantially between in vitro and in vivo models.
In 2014 and 2015, synthetic cannabinoid receptor agonists n class="Chemical">NNEI (N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide) and MN-18 (N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide) were detected in recreationally used and abused products in multiple countries, and were implicated in episodes ofpoisoning and toxicity. Despite this, the pharmacokinetic profiles ofNNEI and MN-18 have not been characterized. In the present study NNEI and MN-18 were incubated in rat and human liver microsomes and hepatocytes, to estimate kinetic parameters and to identify potential metabolic pathways, respectively. These parameters and pathways were then examined in vivo, via analysis of blood and urine samples from catheterized male ratsfollowing intraperitoneal (3 mg/kg) administration ofNNEI and MN-18. Both NNEI and MN-18 were rapidly cleared by rat and human liver microsomes, and underwent a range of oxidative transformations during incubation with rat and human hepatocytes. Several unique metabolites were identified for the forensic identification ofNNEI and MN-18 intake. Interestingly, NNEI underwent a greater number of biotransformations (20 NNEI metabolites versus 10 MN-18 metabolites), yet parent MN-18 was eliminated at a faster rate than NNEI in vivo. Additionally, in vivo elimination was more rapid than in vitro estimates. These data highlight that even closely related synthetic cannabinoids can possess markedly distinct pharmacokinetic profiles, which can vary substantially between in vitro and in vivo models.
Authors: Antoni R Blaazer; Jos H M Lange; Martina A W van der Neut; Arie Mulder; Femke S den Boon; Taco R Werkman; Chris G Kruse; Wytse J Wadman Journal: Eur J Med Chem Date: 2011-08-23 Impact factor: 6.514
Authors: Ragnar Thomsen; Line M Nielsen; Niels B Holm; Henrik B Rasmussen; Kristian Linnet Journal: Drug Test Anal Date: 2014-10-24 Impact factor: 3.345
Authors: Samuel D Banister; Michael Moir; Jordyn Stuart; Richard C Kevin; Katie E Wood; Mitchell Longworth; Shane M Wilkinson; Corinne Beinat; Alexandra S Buchanan; Michelle Glass; Mark Connor; Iain S McGregor; Michael Kassiou Journal: ACS Chem Neurosci Date: 2015-07-17 Impact factor: 4.418
Authors: Ariane Wohlfarth; Adarsh S Gandhi; Shaokun Pang; Mingshe Zhu; Karl B Scheidweiler; Marilyn A Huestis Journal: Anal Bioanal Chem Date: 2014-02-12 Impact factor: 4.142
Authors: Maria Andersson; Xingxing Diao; Ariane Wohlfarth; Karl B Scheidweiler; Marilyn A Huestis Journal: Rapid Commun Mass Spectrom Date: 2016-04-30 Impact factor: 2.419
Authors: Lisa K Brents; Emily E Reichard; Sarah M Zimmerman; Jeffery H Moran; William E Fantegrossi; Paul L Prather Journal: PLoS One Date: 2011-07-06 Impact factor: 3.240
Authors: Richard C Kevin; Timothy W Lefever; Rodney W Snyder; Purvi R Patel; Timothy R Fennell; Jenny L Wiley; Iain S McGregor; Brian F Thomas Journal: Forensic Toxicol Date: 2017-03-10 Impact factor: 4.096
Authors: Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Julie A Marusich; Richard C Kevin; Iain S McGregor; Jenny L Wiley; Brian F Thomas Journal: J Pharmacol Exp Ther Date: 2018-03-16 Impact factor: 4.030
Authors: Thomas F Gamage; Daniel G Barrus; Richard C Kevin; David B Finlay; Timothy W Lefever; Purvi R Patel; Megan A Grabenauer; Michelle Glass; Iain S McGregor; Jenny L Wiley; Brian F Thomas Journal: Pharmacol Biochem Behav Date: 2020-04-02 Impact factor: 3.533